Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs.

It is generally difficult to block protein-protein interactions with small-molecule drugs. A novel pharmaceutical development strategy to block protein interactions is emerging: targeted covalent modification to sterically block interactions. By this approach, compounds first interact non-covalently with a specific target protein. This interaction juxtaposes a weakly reactive group of the drug with a target amino acid sidechain, which then react by virtue of their high local concentration.

[1]  B Kohl,et al.  From peptide to non-peptide. 3. Atropisomeric GPIIbIIIa antagonists containing the 3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione nucleus. , 1997, Journal of medicinal chemistry.

[2]  W. Denny,et al.  Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Zutshi,et al.  Inhibiting the assembly of protein-protein interfaces. , 1998, Current opinion in chemical biology.

[4]  Joseph S. Wall,et al.  Additive Linear Free-Energy Relationships in Reaction Kinetics of Amino Groups with α,β-Unsaturated Compounds1,2 , 1966 .

[5]  N. Kudo,et al.  Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J. Hine,et al.  The Effect of Halogen Atoms on the Reactivity of Other Halogen Atoms in the Same Molecule. III. The SN2 Reactivity of Ethylene Halides1 , 1953 .

[7]  T. Maugh.  Sickle cell (II): many agents near trials. , 1981, Science.

[8]  H. Brown,et al.  Rates of Solvolysis of the Halophenyldimethylcarbinyl Chlorides. The Effect of Halogen Substituents upon the Rates of Electrophilic Reactions1-3 , 1957 .

[9]  J. Widom,et al.  Structure of human methionine aminopeptidase-2 complexed with fumagillin. , 1998, Science.

[10]  B. Eisele,et al.  Stereospecific alkylation with asymmetric reagents. , 1968, European journal of biochemistry.

[11]  S. Watowich,et al.  Crystal structures of influenza virus hemagglutinin in complex with high-affinity receptor analogs. , 1994, Structure.

[12]  P. Corran,et al.  The reaction of penicillin with proteins. , 1975, The Biochemical journal.

[13]  A Whitty,et al.  Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. , 1997, Journal of medicinal chemistry.

[14]  D. R. Holland,et al.  Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand. , 1997, Journal of medicinal chemistry.

[15]  P. Hajduk,et al.  NMR-based discovery of phosphotyrosine mimetics that bind to the Lck SH2 domain. , 1999, Bioorganic & medicinal chemistry letters.

[16]  G. Powers,et al.  Identification of a Small Molecule Inhibitor of the IL-2/IL-2Rα Receptor Interaction Which Binds to IL-2 , 1997 .

[17]  P. Hajduk,et al.  Discovering High-Affinity Ligands for Proteins , 1997, Science.

[18]  C. Walsh,et al.  Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. , 1996, Biochemistry.

[19]  J. Strominger,et al.  Penicillins and cephalosporins are active site-directed acylating agents: evidence in support of the substrate analogue hypothesis. , 1980, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[20]  Hong Wang,et al.  FP-21399 blocks HIV envelope protein-mediated membrane fusion and concentrates in lymph nodes , 1997, Nature Biotechnology.

[21]  I. M. Klotz,et al.  Structural specificities in acylation of hemoglobin and sickle hemoglobin by diaspirins. , 1981, The Journal of biological chemistry.

[22]  T. Inukai,et al.  Rates of Solvolysis of the m- and p-Phenyl-, m- and p-Methylthio-, and m- and p- Trimethylsilylphenyldimethylcarbinyl Chlorides. Steric Inhibition of Resonance as a Factor in Electrophilic Substituent Constants1,2 , 1958 .

[23]  Joseph S. Wall,et al.  Relative Nucleophilic Reactivities of Amino Groups and Mercaptide Ions in Addition Reactions with α,β-Unsaturated Compounds1,2 , 1965 .

[24]  I. M. Klotz,et al.  Rational approaches to chemotherapy: antisickling agents. , 1981, Science.

[25]  Geoffrey,et al.  The acetylation of hemoglobin by aspirin. In vitro and in vivo. , 1975, The Journal of clinical investigation.

[26]  I. M. Klotz,et al.  Modification of hemoglobin with analogs of aspirin. , 1980, The Journal of biological chemistry.

[27]  A. Bogan,et al.  Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.

[28]  R. Heinrikson,et al.  THE REACTIVITIES OF THE HISTIDINE RESIDUES AT THE ACTIVE SITE OF RIBONUCLEASE TOWARD HALO ACIDS OF DIFFERENT STRUCTURES. , 1965, The Journal of biological chemistry.

[29]  L. Marnett,et al.  Aspirin-like molecules that covalently inactivate cyclooxygenase-2. , 1998, Science.

[30]  Minoru Yoshida,et al.  CRM1 Is an Export Receptor for Leucine-Rich Nuclear Export Signals , 1997, Cell.

[31]  G. Stewart.  Allergy to penicillin and related antibiotics: antigenic and immunochemical mechanism. , 1973, Annual review of pharmacology.

[32]  A. D. de Weck,et al.  Studies on the direct neutral penicilloylation of functional groups occurring on proteins. , 1968, Biochimica et biophysica acta.